Wall Street analysts tipped 2024 as the year that medtech dealmaking would return after a two-year slowdown when companies were forced to navigate a tough economic environment complicated by lingering pressures from the COVID-19 pandemic.
Johnson & Johnson shook up the medtech M&A market in early April with its $13.1 billion proposal to buy Shockwave Medical. The acquisition, which closed in May, is the largest of the year so far.
Boston Scientific has proposed billion-dollar deals for Axonics and Silk Road Medical. However, the company pushed back its estimated closure of the $3.7 billion Axonics purchase to the second half of the year after the Federal Trade Commission requested the companies provide additional information.
More recent deals include J&J’s acquisition of heart failure implant maker V-Wave for up to $1.7 billion, Baxter’s agreement to sell its kidney care business to Carlyle Group for $3.8 billion and Owens & Minor’s $1.36 billion takeover of medical equipment company Rotech Healthcare Holdings.
Edwards has also had a recent run of M&A activity, including selling its critical care business to BD for $4.2 billion.
Here’s a collection of MedTech Dive’s coverage of dealmaking so far in 2024. The roundup will be updated as more deals are announced:
